Epidemiology of lower urinary tract symptoms in a cross-sectional, population-based study The status in China

Jian-Ye Wang, MD, PhD^a, Limin Liao, MD, PhD^{b,*}, Ming Liu, MD, PhD^a, Budiwan Sumarsono, MD, MSc^c, Min Cong, MMed^d

Abstract

Lower urinary tract symptoms (LUTS) are reported to affect over half of all adults, and they are associated with significantly impaired quality of life (QOL). We performed a population-based study to evaluate the overall prevalence and impact of LUTS including overactive bladder (OAB) in adults aged \geq 40 years in China.

Adults aged \geq 40 years were eligible to participate in this internet-based survey, provided that they had the ability to access the internet, to use a computer and to read the local language. The survey contained questions relating to International Continence Society (ICS) symptom definitions, the International Prostate Symptom Score (IPSS) and the Overactive Bladder Symptom Score (OABSS). The primary study objective was to determine the prevalence of LUTS using the ICS 2002 symptom definition.

Among the 4136 respondents, 2080 (50.3%) were men and 1347 (32.6%) were aged \geq 60 years. LUTS prevalence according to ICS criteria was 60.3% in men and 57.7% in women. All 3 ICS symptom groups (voiding, storage, and postmicturition) were present in 22.8% of women and 24.2% of men, making this the most common combination of ICS symptom groups. The most bothersome symptoms were terminal dribble and nocturia. According to IPSS scores, 32.9% of participants had at least moderate symptoms. The prevalence of OAB was 23.9%. The presence of LUTS—particularly all 3 ICS symptom groups—was associated with reduced sexual QOL in women, reduced satisfaction with erectile function in men, higher anxiety and depression scores, and reduced health-related QOL (physical health and mental health domains). The overall percentage of participants with LUTS visiting healthcare professionals for urinary symptoms was 38%.

In conclusion, LUTS affect the majority of adults aged ≥40 years in China, and prevalence increases with increasing age. LUTS are associated with impaired QOL and mental health, but fewer than half of individuals in China with LUTS seek healthcare for their symptoms. There is therefore a need to improve awareness and treatment of the condition.

ClinicalTrials.gov identifier: NCT02618421

Abbreviations: HADS = Hospital Anxiety and Depression Scale, HRQOL = health-related quality of life, ICS = International Continence Society, IIEF = International Index of Erectile Function, IPSS = International Prostate Symptom Score, LUTS = lower urinary tract symptoms, OAB = overactive bladder, OABSS = Overactive Bladder Symptom Score, QOL = quality of life, SQOL-F = sexual quality of life—female, SUI = stress urinary incontinence.

Keywords: China, epidemiology, lower urinary tract symptoms, overactive bladder, prevalence

1. Introduction

The term lower urinary tract symptoms (LUTS) encompasses a wide variety of different symptoms. According to the International Continence Society (ICS), they can be classified into 3

Editor: Ran Pang.

This study was funded by Astellas Pharma Singapore Pte. Ltd.

Medicine (2018) 97:34(e11554)

Received: 20 September 2017 / Accepted: 24 June 2018 http://dx.doi.org/10.1097/MD.000000000011554 categories: voiding, storage, and postmicturition.^[1] Although LUTS are not usually life-threatening, under-recognition, which contributes to suboptimal treatment, and under-treatment are significant issues as they increase the overall symptom burden. Epidemiological studies are valuable in providing an insight into real-world prevalence and impact of LUTS. The use of ICS terminology when conducting such studies can be helpful in ensuring that the results of different epidemiological studies are comparable.

International studies have shown that LUTS affect over half of all adults, with increasing prevalence among older age groups.^[2,3] In China, a population-based survey conducted across 5 regions, using the International Consultation on Incontinence Questionnaire Male/Female Lower Urinary Tract Symptoms Long Form, reported that 61% of men and women aged \geq 18 years had at least 1 LUTS.^[4]

Individuals with LUTS have significantly impaired quality of life (QOL).^[5–8] For example, in a study of Chinese LUTS patients, poorer health-related quality of life (HRQOL) was evident in relation to the general health domain, vitality domain and physical component summary, compared with normal values for the Hong Kong population.^[5] A greater impact on QOL was

The authors have no conflicts of interest to disclose.

^a Department of Urology, Beijing Hospital, ^b Department of Urology, China Rehabilitation Research Center, Capital Medical University, Beijing, China, ^c Astellas Pharma Singapore Pte. Ltd., Singapore, ^d Astellas Pharma China, Inc., Beijing, China.

^{*} Correspondence: Limin Liao, Department of Urology, China Rehabilitation Research Center, Capital Medical University, Beijing, China (e-mail: Imliao@263.net).

Copyright © 2018 the Author(s). Published by Wolters Kluwer Health, Inc. This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

evident in patients with nocturia, frequency, urgency, or mixed urinary incontinence, and in those affected at a young age. LUTS can have significant pharmacoeconomic impact, with costs arising through the purchase of incontinence pads and reduced workplace productivity.^[9–11] In addition, individuals with LUTS have increased risk of mental health problems such as depression and anxiety.^[10,12] Consequently, considerable benefits can be gained from optimal therapy of LUTS. However, many individuals with symptoms do not consult a healthcare professional for treatment.^[13]

We performed a population-based study to evaluate the overall prevalence and impact of LUTS including overactive bladder (OAB) in adults aged ≥40 years in China, Taiwan, and South Korea. The combined results from all 3 countries are available elsewhere.^[14–16] The prevalence data indicate that LUTS affects approximately 60% of the combined population, with a slightly higher rate in men than women (62.8% vs 59.6%; P = .004).^[14] LUTS prevalence was shown to increase significantly with age (P=.001). OAB was present in 19.5% of men and 22.1% of women and, as with LUTS, there was a significant increase in OAB prevalence with increasing age (P=.001).^[15] HRQOL was also impaired among individuals with LUTS, with a corresponding increase in levels of anxiety and depression.^[16] Here, by presenting data from this study relating to 1 country, we aim to provide a more detailed insight into LUTS prevalence and burden specifically in China.

2. Methods

This international study was conducted using an internet-based survey between June 2 and July 20, 2015. The methods have been published in full previously.^[14] Therefore, in this publication we are providing a short description only.

Adults aged \geq 40 years living in the general community were eligible to participate, provided that they had the ability to access the internet, to use a computer (with help, if required) and to read the local language. Individuals who had a urinary tract infection within the preceding month were excluded as were women who were pregnant at the time of the survey. Participants were selected via consumer survey panels, with email invitations sent to prevalidated individuals. To address possible bias, the demographic profile of the study population (age, sex, and socioeconomic factors) was actively managed within each survey panel.

The survey contained questions relating to ICS symptom definitions,^[1] the International Prostate Symptom Score (IPSS) and the Overactive Bladder Symptom Score (OABSS). In addition, HRQOL, the Hospital Anxiety and Depression Scale (HADS), the International Index of Erectile Function (IIEF, completed by men only), and Sexual Quality of Life—Female (SQOL-F, completed by women only) were included.

The primary study objective was to determine the prevalence of LUTS using the ICS 2002 symptom definition. Secondary objectives included assessment of the associations of LUTS with HRQOL, HADS scores, and SQOL-F and IIEF scores. The degree of symptom-specific bother of LUTS was assessed using a Likert scale: not at all ([score 0], a little bit [score 1], somewhat [score 2], quite a bit [score 3] or a great deal [score 4]). A score <2 suggested that there was no or only a little bit of associated bother while a score ≥ 2 indicated "somewhat or greater bother" and a score ≥ 3 was the most severe degree of bother, "quite a bit or greater." In addition, the prevalence of OAB was measured using OABSS.

For assessment of the percentage of the population with a particular LUTS characteristic and with a 95% confidence interval, it was calculated that \geq 384 participants would be required per age group, increasing to 1920 for 5 different age groups. Approximately, 28% of data were expected to be nonevaluable (e.g., missing/inconsistent information) and, consequently, total enrollment of at least 2667 respondents was planned. Initial data analyses were based on descriptive statistics. There was no imputation for missing values: respondents who completed the relevant sections of the questionnaire were included in the analysis and the rest were excluded. As it was a web survey with logical checks, it was confirmed that all answers were coherent. Post-hoc statistical comparisons were chosen for consistency with the EpiLUTS study,^[2] with comparisons performed principally using the Chi-square test. Differences were considered to be statistically significant with Pvalues $\leq .05$. A step-wise multiple logistic regression analysis was performed with treatment seeking as the binary independent variable. A total of 29 independent variables were included in the model, including continuous, categorical and binary variables. The final set of variables was chosen according to clinical relevance. Data analyses were performed using R (3.2.1) (R Foundation for Statistical Computing, Vienna, Austria), SPSS Base 15 (SPSS Inc., Chicago, IL) and Microsoft Excel 2016 (Microsoft Corp., Redmond, WA).

Institutional review board approval was not considered necessary for this study as it was based on a survey. However, principles of the Declaration of Helsinki were followed, and the study was performed in compliance with Good Clinical Practice

Table 1

Sex	
Men	2080 (50.3%)
Women	2056 (49.7%)
Age group	
40-44 years	821 (19.9%)
45–49 years	809 (19.6%)
50–54 years	633 (15.3%)
55–59 years	526 (12.7%)
≥60 years	1347 (32.6%)
Education	
High-school or less	1157 (28.0%)
Some college	1174 (28.4%)
College degree/college graduate	1661 (40.2%)
Postgraduate	144 (3.5%)
Marital status	
Single	120 (2.9%)
Divorced	60 (1.5%)
Married/living with partner	3793 (91.7%)
Widow/widower	132 (3.2%)
Prefer not to answer	32 (0.8%)
Work status	
Homemaker	108 (2.6%)
Retired	1188 (28.7%)
Student	2 (0.0%)
Working, full-time	2588 (62.6%)
Working, part-time	154 (3.7%)
Other work for pay	17 (0.4%)
Other	46 (1.1%)
Unemployed	27 (0.6%)
Permanently disabled/cannot work due to ill health	5 (0.1%)


Data shown are n (%); N=4136. Table adapted from Chapple et al.^[14]


and market research guidelines. Prior to participation in the study, all participants provided informed consent.


3. Results

A total of 399,215 email invitations were sent to Chinese individuals. Informed consent was obtained from 13,819 individuals, of whom 9683 were excluded either because the survey quota had already been filled or because the individual had completed the survey rapidly/superficially (i.e., unreliable results). Thus, surveys from 4136 respondents were analyzed; 2080 respondents (50.3%) were men and 1347 (32.6%) were aged ≥ 60 years (Table 1).

LUTS prevalence according to ICS criteria was slightly higher in men (60.3%) than in women (57.7%; Fig. 1A). All 3 ICS symptom groups (voiding, storage, and postmicturition) were present in 23.5% of individuals (women: 22.8%, men: 24.2%), making this the most common combination of ICS symptom







groups (Fig. 1A). The second most common symptom type was storage symptoms only (15.9%); this was more prevalent in women than in men (20.4% vs 11.4%). A combination of storage and voiding symptoms was third most common, with a prevalence of 10.3% (women: 9.7%, men: 10.9%). Voiding symptoms only were more prevalent in men than women (6.4% vs 1.6%). In both men and women, LUTS prevalence showed a tendency to increase with age (P < .001, Chi-square test) (Fig. 2).

Symptoms with the highest overall prevalence were nocturia (38%), perceived frequency (30%), terminal dribble (29%), and incomplete emptying (26%) (Fig. 3). In men, the 2 most prevalent symptoms were nocturia (35%) and terminal dribble (32%); those in women were nocturia (41%) and perceived frequency (31%). The most bothersome symptoms (those with the largest numbers of participants experiencing "quite a bit or greater" bother) were terminal dribble and nocturia (Fig. 3). These were followed by intermittency, incomplete emptying, perceived




Figure 3. Prevalence in China of specific symptoms and bother: men and women. Bother score based on percentage of patients who experienced the symptom; numbers at top of bar represent overall prevalence. Score <2: no or a little bit of bother; score \geq 2: somewhat or greater bother; score \geq 3: quite a bit or greater bother.

International Prostate Symptom Score quality of life according to International Prostate Symptom Score symptom severity in Chinese men (A; n = 1856) and women (B; n = 1814).

	Participants with IPSS symptoms, n (%)					
Quality of life rating	No symptoms	Mild	Moderate	Severe		
A.						
Delighted	8 (11%)	70 (6%)	9 (2%)	1 (1%)		
Pleased	25 (35%)	265 (24%)	33 (6%)	8 (5%)		
Mostly satisfied	13 (18%)	180 (17%)	89 (16%)	7 (5%)		
Mixed—about equally satisfied and dissatisfied	7 (11%)	255 (24%)	111 (20%)	12 (8%)		
Mostly dissatisfied	4 (5%)	156 (14%)	157 (28%)	24 (16%)		
Unhappy	5 (7%)	98 (9%)	123 (22%)	61 (41%)		
Terrible	9 (13%)	59 (5%)	36 (6%)	34 (23%)		
Mostly dissatisfied or greater	18 (25%)	313 (29%)	315 (57%)	118 (81%)		
Unhappy or greater B.	14 (20%)	157 (14%)	159 (28%)	94 (64%)		
Delighted	9 (12%)	69 (6%)	13 (3%)	0 (0%)		
Pleased	25 (35%)	283 (26%)	44 (10%)	5 (3%)		
Mostly satisfied	13 (17%)	184 (17%)	67 (15%)	14 (7%)		
Mixed—about equally satisfied and dissatisfied	9 (12%)	246 (23%)	69 (15%)	26 (13%)		
Mostly dissatisfied	4 (6%)	158 (15%)	134 (29%)	49 (24%)		
Unhappy	5 (7%)	95 (9%)	109 (24%)	67 (33%)		
Terrible	8 (11%)	47 (4%)	22 (5%)	39 (19%)		
Mostly dissatisfied or greater	17 (24%)	300 (28%)	266 (58%)	154 (77%)		
Unhappy or greater	13 (18%)	141 (13%)	132 (29%)	105 (53%)		

IPSS = International Prostate Symptom Score.

frequency, urgency, and urgency with fear of leaking. Therefore, 4 of the 7 most bothersome symptoms were related to storage. The overall prevalence of stress urinary incontinence (SUI) was 22.0%, with rates of 16.8% in men and 27.2% in women.

According to IPSS scores, 85.2% of participants had at least mild symptoms. Prevalence of moderate or greater symptoms (IPSS score ≥ 8) was 32.9% (Fig. 1B). For men and women with moderate symptoms, IPSS QOL was "unhappy" or worse in 29% of participants, and the corresponding percentage among individuals with severe symptoms was 58%. Sex-specific IPSS QOL data are shown in Table 2; only minor differences were evident between men and women.

Table 3

Overactive bladder prevalence in China by comorbidities (data for men and women combined, n=4136).

	OAB prevalence (%)		
	Present	Absent	
Diabetes	50.7%	18.6%	
High blood pressure	36.1%	18.5%	
Cardiac disease	43.1%	21.4%	
Hyperlipidemia	31.5%	21.3%	
Neurological disorders	53.1%	22.4%	
Smoking	33.2%	20.9%	
Alcohol consumption	33.2%	21.2%	


Overactive prevalence was significantly higher among individuals with versus without every comorbidity (P < .001).

OAB = overactive bladder.

The prevalence of OAB, as determined by OABSS, was 23.9%: 21.4% in men and 26.4% in women (Fig. 1). In comparison, the overall prevalence of storage symptoms was 51.8%. All comorbid conditions investigated were associated with significantly higher OAB prevalence rates (P < .001; Table 3). The presence of diabetes was associated with the greatest increase in OAB prevalence, from 18.6% in individuals without the condition to 50.7% in those with diabetes. The impact of comorbid conditions on OAB prevalence was similar in men and women (data not shown).

Approximately three-quarters of individuals reported ≥ 1 episode of nocturia per night (Fig. 4), and similar percentages of men and women were affected (74.4% and 77.4%, respectively). The prevalence of nocturia ≥ 2 episodes per night was 37.9% (men: 35.2%, women: 40.6%). In both men and women, the prevalence of nocturia (≥ 1 or ≥ 2 episodes per night) increased with age. There was 1 exception to the age-related trend: in women aged >60 years, the prevalence of ≥ 2 episodes per night was lower than that in those aged 55–60 years (54.7%) vs 56.7%).

Women with all 3 ICS symptom categories—voiding, storage, and postmicturition—had a lower sexual QOL (SQOL-F mean score 64.5) than those experiencing other ICS symptom combinations (66.8–81.8; Table 4). Sexual QOL was the highest among women without LUTS, with a mean SQOL-F score of 87.2. Among men, the presence of LUTS was associated with



Lower urinary tract symptoms in China according to International Continence Society symptoms and female sexual quality of life.

ICS symptoms	SQOL-F—mean (SD) score [*] (women, $n = 1630$)
No LUTS	87.2 (23.3)
Voiding only	75.6 (30.1)
Storage only	80.1 (23.1)
PM only	81.8 (18.7)
Voiding and storage	66.8 (22.1)
Voiding and PM	71.5 (17.9)
Storage and PM	77.6 (25.1)
Voiding, storage, and PM	64.5 (22.2)
Overall	76.8 (24.8)
Any LUTS	71.3 (23.8)

Score range 18-108; higher scores indicate better sexual quality of life.

ICS=International Continence Society, LUTS=Iower urinary tract symptoms; PM=postmicturition, SQ0L-F=sexual quality of life—female.

reduced IIEF overall satisfaction and, as in women, the greatest negative effect was observed in those with all 3 symptom categories (Table 5). Mean IIEF overall satisfaction scores were 5.5 in men with voiding, storage, and postmicturition symptoms, 6.2 to 7.0 in men with other ICS symptoms, and 7.3 in those without LUTS.

Lower HRQOL (SF-12) scores were observed in both physical health and mental health domains among individuals with versus without LUTS according to ICS criteria (Table 6). The largest decreases were apparent in those with voiding, storage, and postmicturition symptoms. The presence of LUTS was also associated with higher HADS anxiety and depression scores (Table 7). As with QOL, the greatest impairment was seen among individuals with voiding, storage, and postmicturition symptoms.

The overall percentage of participants with LUTS visiting healthcare professionals for urinary symptoms was 38%, rising to 59% in those with voiding, storage, and postmicturition symptoms (Fig. 5). For individuals with voiding, storage, and postmicturition symptoms, the most common LUTS treatments were prescription medication, limiting intake of fluids, physical therapy, and self-treatment (Table 8). The same treatments were most commonly used by individuals with other ICS symptom combinations. Physical therapy was more commonly used by women than by men.

Table 5

Lower urinary tract symptoms in China according to International Continence Society symptoms and International Index of Erectile Function overall satisfaction.

ICS symptoms	IIEF, overall satisfaction—mean (SD) score * (men, n = 1253)
No LUTS	7.3 (1.5)
Voiding only	6.7 (1.4)
Storage only	6.9 (1.6)
PM only	7.0 (1.1)
Voiding and storage	6.2 (1.8)
Voiding and PM	6.5 (1.6)
Storage and PM	6.6 (1.5)
Voiding, storage, and PM	5.5 (1.6)
Overall	6.5 (1.7)
Any LUTS	6.2 (1.7)

* Score range 0–10; higher scores indicate lower dysfunction.

IIEF=International Index of Erectile Function, LUTS=lower urinary tract symptoms, $\mathsf{PM}=\mathsf{postmicturition}.$

Based on logistic regression results, the presence of comorbid conditions (diabetes and hypertension) and specific urinary symptoms (hesitancy, perceived frequency, nocturia, nocturnal enuresis, urgency with fear of leaking, urge incontinence, and stress incontinence [exercising]) were significant predictors of seeking treatment for urinary symptoms (Table 9).

4. Discussion

This study represents the largest population-based survey to date of LUTS among men and women in China. The results show that LUTS affect more than half of the Chinese population aged \geq 40 years, and that the prevalence increases with age. Nocturia was the most common symptom, with approximately three-quarters of individuals reporting \geq 1 episode per night and more than onethird reporting \geq 2 episodes per night. In a given individual, multiple LUTS are more likely to be present than 1 symptom alone, and bothersome symptoms are common. The overall LUTS prevalence was similar in men and women but, as expected, storage symptoms including SUI were more common in women and voiding symptoms were more common in men. LUTS prevalence was measured by both ICS and IPSS criteria, but the ICS data may be considered as more definitive. IPSS was initially

Table 6

Health-related quality of life score, Short Form-12 (physical health domain and mental health domain) in China by International Continence Society symptoms.

	Mean (SD) physical health (domain score [*]	Mean (SD) mental health domain score *			
ICS symptoms	Men (n=2080)	Women (n = 2056)	Men and women (n = 4136)	Men (n = 2080)	Women (n = 2056)	Men and women (n = 4136)	
No LUTS	78.7 (16.8)	75.0 (17.6)	76.8 (17.3)	44.9 (10.6)	43.3 (10.4)	44.1 (10.5)	
Voiding only	70.5 (18.2)	66.7 (17.8)	69.7 (18.1)	40.2 (11.7)	37.2 (9.7)	39.6 (11.4)	
Storage only	69.9 (19.2)	63.0 (18.4)	65.5 (19.0)	39.6 (12.8)	37.1 (11.5)	38.0 (12.1)	
PM only	69.5 (16.8)	56.6 (20.2)	65.8 (18.6)	40.2 (11.3)	32.5 (13.5)	38.0 (12.4)	
Voiding and storage	55.9 (18.9)	49.6 (17.6)	53.0 (18.5)	33.0 (13.0)	27.5 (11.6)	30.4 (12.7)	
Voiding and PM	69.0 (16.4)	59.2 (16.6)	67.6 (16.7)	38.4 (11.9)	33.0 (11.3)	37.6 (11.9)	
Storage and PM	59.6 (19.3)	62.0 (17.7)	60.7 (18.5)	33.1 (12.6)	35.4 (11.3)	34.1 (12.0)	
Voiding, storage, and PM	49.3 (17.5)	44.2 (15.9)	46.9 (16.9)	28.2 (11.6)	25.2 (9.3)	26.8 (10.7)	
Overall	66.6 (21.4)	62.4 (21.5)	64.5 (21.5)	38.1 (13.4)	36.0 (13.0)	37.0 (13.2)	
Any LUTS	58.7 (20.3)	53.3 (19.3)	56.1 (20.0)	33.6 (13.2)	30.6 (12.0)	32.2 (12.7)	

* The SF-12 physical and mental health domain scores range from 0 to 100, with higher scores representing better health.

ICS=International Continence Society, LUTS=lower urinary tract symptoms, PM=postmicturition, SD=standard deviation, SF=short-form.

Hospital Anxiety and Depression Scale anxiety score and Hospital Anxiety and Depression Scale depression score in China by International Continence Society symptoms.

	М	ean (SD) HADS anxie	ety score [*]	Mean (SD) HADS depression score [*]			
ICS symptoms	Men (n = 2080)	Women (n = 2056)	Men and women (n=4136)	Men (n = 2080)	Women (n = 2056)	Men and women (n=4136)	
No LUTS	3.6 (3.2)	4.1 (3.4)	3.9 (3.3)	3.3 (3.0)	3.9 (3.5)	3.6 (3.3)	
Voiding only	4.8 (3.5)	5.8 (3.3)	5.0 (3.5)	4.8 (3.5)	6.1 (4.2)	5.0 (3.6)	
Storage only	5.0 (3.4)	5.7 (3.3)	5.4 (3.3)	4.4 (3.3)	5.2 (3.4)	4.9 (3.3)	
PM only	5.0 (2.9)	6.5 (2.8)	5.4 (2.9)	4.7 (2.9)	6.2 (3.2)	5.1 (3.0)	
Voiding and storage	6.5 (3.6)	7.2 (3.5)	6.8 (3.6)	6.1 (3.6)	7.1 (3.8)	6.6 (3.7)	
Voiding and PM	5.8 (3.5)	6.4 (1.6)	5.8 (3.3)	5.3 (4.0)	5.1 (3.2)	5.3 (3.8)	
Storage and PM	6.9 (3.5)	6.6 (3.8)	6.7 (3.6)	5.6 (3.4)	6.6 (4.1)	6.0 (3.7)	
Voiding, storage, and PM	8.0 (3.6)	9.0 (3.3)	8.5 (3.5)	7.3 (3.5)	9.2 (4.0)	8.2 (3.8)	
Overall	5.4 (3.8)	5.9 (3.9)	5.7 (3.9)	4.9 (3.7)	5.8 (4.2)	5.4 (3.9)	
Any LUTS	6.6 (3.8)	7.3 (3.6)	6.9 (3.7)	6.0 (3.7)	7.2 (4.1)	6.6 (3.9)	

* HADS anxiety and depression scores range from 0 to 21, with higher scores representing increased levels of anxiety or depression.

HADS = Hospital Anxiety and Depression Scale, ICS = International Continence Society, LUTS = lower urinary tract system, PM = postmicturition.

designed to assess men with benign prostatic hyperplasia; it contains only 3 questions on storage and none on postmicturition symptoms; and it is less effective than ICS for distinguishing between individual symptoms.^[3,17]

A number of previous surveys have assessed LUTS prevalence worldwide and in China, some of which have reported similar findings to the present study. For example, Wang et al^[4] reported a prevalence rate of 61% among Chinese adults aged >18 years, similar to the prevalence of 64% from the EPIC study that was conducted in 4 European countries and Canada.^[3] In both studies, prevalence increased with age and nocturia was the most common symptom. In the Chinese study, there was no difference in prevalence between men and women, whereas in the international study and in contrast to our study, prevalence was slightly higher in women (66.6%) than in men (62.5%). A study in adult Chinese women reported that LUTS affects 56% of individuals, and that the prevalence increases with age.^[18] However, some variability in prevalence data has also been observed. A lower LUTS prevalence of 40% was reported in Chinese women aged ≥ 20 years completing the Bristol female lower urinary tract symptoms questionnaire,^[19] while a higher prevalence of LUTS according to IPSS was reported by Yee et al,^[20] with moderate-to-severe symptoms occurring in 69% of men aged \geq 40 years. Possible contributors to this variability include conducting surveys in different geographical areas, introducing cultural/ethnicity differences; the use of different survey methods; sample size (if too small, results may not reflect the overall population); and demographic characteristics of study populations. Considering the size of the present study, we are confident that our results can be generalized to the overall population in China, although differences between regions cannot be excluded.

The association between age and LUTS prevalence reflects previous observations. The profile of symptoms can change with age—for example, erectile dysfunction and ejaculatory dysfunction are much more likely to be found among men aged over 70 than those aged 50 to 54.^[21] The association we found between LUTS and impairment of QOL is also as expected: such associations have been observed in studies performed both in China^[5,8] and other countries.^[6,11,22–25] It has been reported




Figure 5. Healthcare according to ICS symptoms: individuals visiting a healthcare professional in China for urinary symptoms. *~11% did not answer. †~12% did not answer. ICS=International Continence Society, LUTS=lower urinary tract symptoms, PM=postmicturition.

Treatment for lower urinary tract symptoms in China (men and women).

	Participants reporting treatment according to ICS symptoms, n (%)							
Treatments for urinary symptoms	PM only	Storage and PM	Storage only	Voiding and PM	Voiding and storage	Voiding, storage and PM	Voiding only	P [*]
Men, n	43	48	234	63	227	504	133	
Prescription medications	6.0 (14.0)	15.0 (31.2)	54.0 (23.0)	7.0 (11.1)	66.0 (29.1)	199.0 (39.5)	15.0 (11.3)	<.001
Surgery	0 (0)	1.0 (2.1)	2.0 (0.9)	1.0 (1.6)	6.0 (2.6)	9.0 (1.8)	2.0 (1.5)	.797
Physical therapy: exercise or training recommended by a healthcare professional	6.0 (14.0)	9.0 (18.8)	31.0 (13.2)	5.0 (7.9)	62.0 (27.3)	148.0 (29.4)	4.0 (3.0)	<.001
Self-treatment: herbal remedies or over the counter medicines, exercise recommended by friend/family	6.0 (14.0)	16.0 (33.3)	32.0 (13.7)	7.0 (11.1)	74.0 (32.6)	177.0 (35)	18.0 (13.5)	<.001
Limiting intake of fluids	2.0 (4.7)	16.0 (34.0)	36.0 (15.4)	5.0 (7.9)	66.0 (29.1)	188.0 (37.3)	9.0 (6.7)	<.001
Limiting intake of caffeine	0 (0)	6.0 (12.5)	12.0 (5.1)	1.0 (1.6)	21.0 (9.3)	76.0 (15.1)	4.0 (3.0)	<.001
Limiting intake of alcohol	6.0 (14)	11.0 (22.9)	19.0 (8.1)	4.0 (6.3)	50.0 (22.0)	115.0 (22.8)	7.0 (5.3)	<.001
Not drinking after a certain time at night	0 (0)	8.0 (16.7)	20.0 (8.5)	3.0 (4.8)	38.0 (16.7)	111.0 (22.0)	11.0 (8.2)	<.001
Wearing pads	0 (0)	1.0 (2.1)	1.0 (0.4)	0 (0)	9.0 (4.0)	31.0 (6.2)	0 (0)	<.001
Women, n	17	39	417	10	198	470	33	
Prescription medications	5.0 (29.4)	14.0 (35.9)	67.0 (16.1)	5.0 (50.0)	63.0 (31.7)	206.0 (43.8)	5.0 (15.2)	<.001
Surgery	0 (0)	1.0 (2.6)	1.0 (0.2)	0 (0)	8.0 (4.0)	17.0 (3.6)	0 (0)	.003
Physical therapy: exercise or training recommended by a healthcare professional	4.0 (23.5)	3.0 (7.7)	47.0 (11.3)	3.0 (30.0)	61.0 (30.7)	197.0 (42.0)	7.0 (21.2)	<.001
Self-treatment: herbal remedies or over the counter medicines, exercise recommended by friend/family	3.0 (17.6)	9.0 (23.1)	59.0 (14.1)	5.0 (50.0)	58.0 (29.1)	166.0 (35.3)	6.0 (18.2)	<.001
Limiting intake of fluids	1.0 (5.9)	12.0 (30.8)	77.0 (18.5)	2.0 (20.0)	64.0 (32.2)	190.0 (40.5)	5.0 (15.2)	<.001
Limiting intake of caffeine	0 (0)	1.0 (2.6)	15.0 (3.6)	2.0 (20)	21.0 (10.6)	82.0 (17.4)	1.0 (3.0)	<.001
Limiting intake of alcohol	1.0 (5.9)	0 (0)	13 (3.1)	0 (0)	9.0 (4.5)	63.0 (13.4)	2.0 (6.1)	<.001
Not drinking after a certain time at night	0 (0)	3.0 (7.7)	15.0 (3.6)	0 (0)	14.0 (7.0)	67.0 (14.3)	1.0 (3.0)	<.001
Wearing pads	0 (0)	4.0 (10.3)	15.0 (3.6)	1.0 (10.0)	12.0 (6.0)	54.0 (11.5)	0 (0)	<.001

* P-value: determined from Chi-square test for proportions.

If P-value is <.05 then the difference across all of the groups is considered to be statistically significant.

ICS = International Continence Society, LUTS = lower urinary tract symptoms, PM = postmicturition.

previously that LUTS may be associated with increased depression/anxiety^[6,11,12,25–27] and worsened IIEF score.^[28]

The presence of LUTS was associated with reduced sexual QOL in women, reduced satisfaction with erectile function in men, higher anxiety and depression scores, and reduced health-related QOL (physical health and mental health domains). All of these effects were greater among individuals with all 3 ICS symptom categories (voiding, storage, and postmicturition) than in those with other symptom combinations. Therefore, LUTS with all 3 ICS symptom categories may be considered to be the most severe form.

OAB is a subset of storage symptoms, so a lower prevalence than that of ICS-defined storage symptoms is in line with expectations. OAB commonly co-exists with other LUTS and it has been shown that men with OAB are likely to report more symptoms and higher severity than those with LUTS but no OAB.^[29] An updated OAB definition has been proposed.^[30] It would be interesting to see how the use of the new definition (as opposed to OABSS criteria) would affect the prevalence of OAB. In a previous study of OAB in China (conducted in men >50 years of age), the prevalence of 26% was similar to the rate of 24% in the current study.^[31] However, a lower prevalence of 2.1% was reported in a community-based study performed using OABSS in Chinese adults aged \geq 40 years.^[32] Other authors have published relatively low estimates of OAB prevalence: 11% among Chinese individuals aged \geq 40 years.^[33] and 6% in those aged \geq 18 years.^[7] In this latter publication, OAB prevalence in men and women aged \geq 50 years was 14.8% versus 16.1%, respectively; the authors commented that, had the symptom frequency of urgency not been emphasized, the prevalence of OAB in those aged \geq 40 years would have been 19.9%.^[7] In the EPIC study, overall OAB prevalence was 12% with similar rates between men and women, although women aged \geq 60 years reported more OAB than younger women, while the reverse was true for men.^[3] Differences between studies in OAB prevalence could be caused by survey methods. Internet-based methodology brings the risk of participants not understanding questions, while embarrassment can be a barrier to truthful responses during face-to-face interviews. It is possible that ethnic or cultural differences between populations could also contribute to variability between studies.

The associations observed in our study between comorbidities and increased OAB prevalence are broadly in line with expectations, although data from different studies are often conflicting. There are mechanistic, possibly causative relationships between some of the comorbidities and OAB. For example, disruption of the mechanisms that affect the pathophysiology of OAB is seen in neurologic disorders^[34] and diabetes can affect bladder function.^[35] Smoking can trigger OAB,^[36] but while we found smoking to be a significant comorbidity, reports of smoking as a risk factor differ and there may even be differences between the sexes.^[37–39] For other comorbidities, underlying risk factors may overlap with the risk factors for OAB (e.g., obesity).

Logistic regression analysis of predictors of treatment-seeking behavior.

Constant 0.04 $0.02-0.10$ <.001	Covariate	Odds ratio	95% confidence interval	P *
Male sex (yes) 0.93 $0.75-1.15$ $.50$ Age (numerical) 1.00 $0.99-1.01$ $.94$ Body mass index (numerical) 1.00 $0.98-1.03$ $.79$ Comorbidities (yes) $0.99-4.78$ $<.001$ High blood pressure 1.49 $1.20-1.85$ $<.001$ Cardiac disease 1.17 $0.86-1.57$ 3.11 Hyperlipidemia 1.04 $0.82-1.30$ $.75$ Neurological disorder 0.89 $0.55-1.41$ $.61$ Urinary symptoms (yes) Voiding symptoms Veak stream 1.12 $0.99-1.27$ $.08$ Split stream 0.33 $0.83-1.05$ $.24$ Intermittency 1.02 $0.90-1.16$ $.73$ Hesitancy 1.26 $1.10-1.45$ $<.001$ Straining 1.07 $0.94-1.22$ $.28$ Terminal dribble 0.91 $0.82-1.02$ $.10$ $Storage symptoms$ Perceived frequency 2.93 $2.35-3.66$ $<.001$ Nocturia 1.22 $1.06-1.39$ $<.001$ Urgency incontinence 1				
Age (numerical)1.00 $0.99-1.01$.94Body mass index (numerical)1.00 $0.98-1.03$.79Comorbidities (yes)Diabetes 3.78 $2.99-4.78$ <.001				
Body mass index (numerical)1.00 $0.98-1.03$.79Comorbidities (yes)Diabetes 3.78 $2.99-4.78$ $<.001$ High blood pressure 1.49 $1.20-1.85$ $<.001$ Cardiac disease 1.17 $0.86-1.57$ $.31$ Hyperlipidemia 1.04 $0.82-1.30$.75Neurological disorder 0.89 $0.55-1.41$.61Urinary symptoms (yes) $Voiding symptoms$ $Voiding symptoms$ $Voiding symptoms$ Weak stream 1.12 $0.99-1.27$.08Split stream 0.93 $0.83-1.05$.24Intermittency 1.02 $0.90-1.16$.73Hesitancy 1.26 $1.10-1.45$ <.001				
Comorbidities (yes) Diabetes 3.78 $2.99-4.78$ $<.001$ High blood pressure 1.49 $1.20-1.85$ $<.001$ Cardiac disease 1.17 $0.86-1.57$ 31 Hyperlipidemia 1.04 $0.82-1.30$ $.75$ Neurological disorder 0.89 $0.55-1.41$ $.61$ Urinary symptoms (yes) Voiding symptoms $.24$ $$				
Diabetes 3.78 $2.99-4.78$ $<.001$ High blood pressure 1.49 $1.20-1.85$ $<.001$ Cardiac disease 1.17 $0.86-1.57$ $.31$ Hyperlipidemia 1.04 $0.82-1.30$ $.75$ Neurological disorder 0.89 $0.55-1.41$ $.61$ Urinary symptoms (yes) $Viding symptoms$ $Viding symptoms$ $Viding symptoms$ Weak stream 1.12 $0.99-1.27$ $.08$ Split stream 0.93 $0.83-1.05$ $.24$ Intermittency 1.02 $0.90-1.16$ $.73$ Hesitancy 1.26 $1.10-1.45$ $<.001$ Straining 1.07 $0.94-1.22$ $.28$ Terminal dribble 0.91 $0.82-1.02$ $.10$ Storage symptoms $Perceived frequency$ 2.93 $2.35-3.66$ $<.001$ Nocturia 1.22 $1.10-1.34$ $<.001$ $Urgency$ 0.94 $0.83-1.06$ $.31$ Urgency with fear of leaking 1.22 $1.06-1.39$ $<.001$ $Urgency^{\dagger}$ $Stress incontinence 1.92$ $1.43-2.57$ $<.001$ Urgency incontinence:laughing 1.03 $0.68-1.54$ $.90$ $Stress incontinence: coughing0.930.67-1.27.64Stress incontinence:laughing1.200.81-1.78.36heavy objectsStress incontinence: infting1.200.81-1.78.36heavy objectsStress incontinence: noturnal2.351.50-3.74<.001enuresis (while sleep)$		1.00	0.98-1.03	.79
High blood pressure1.491.20–1.85<.001Cardiac disease1.170.86–1.57.31Hyperlipidemia1.040.82–1.30.75Neurological disorder0.890.55–1.41.61Urinary symptoms (yes)Voiding symptomsVoiding symptomsWeak stream1.120.99–1.27.08Split stream0.930.83–1.05.24Intermittency1.020.90–1.16.73Hesitancy1.261.10–1.45<.001	0 /			
Cardiac disease 1.17 $0.86-1.57$.31 Hyperlipidemia 1.04 $0.82-1.30$.75 Neurological disorder 0.89 $0.55-1.41$.61 Urinary symptoms (yes) Voiding symptoms				
Hyperlipidemia1.04 $0.82-1.30$.75Neurological disorder 0.89 $0.55-1.41$.61Urinary symptoms (yes) $Voiding symptoms$ $Voiding symptoms$ Weak stream 1.12 $0.99-1.27$.08Split stream 0.93 $0.83-1.05$.24Intermittency 1.02 $0.90-1.16$.73Hesitancy 1.26 $1.10-1.45$ <.001	5 I			
Neurological disorder 0.89 $0.55-1.41$.61Urinary symptoms (yes)Voiding symptomsWeak stream 1.12 $0.99-1.27$.08Split stream 0.93 $0.83-1.05$.24Intermittency 1.02 $0.90-1.16$.73Hesitancy 1.26 $1.10-1.45$ <.001		1.17		
Urinary symptoms (yes) Voiding symptoms Weak stream 1.12 $0.99-1.27$ $.08$ Split stream 0.93 $0.83-1.05$ $.24$ Intermittency 1.02 $0.90-1.16$ $.73$ Hesitancy 1.26 $1.10-1.45$ $<.001$ Straining 1.07 $0.94-1.22$ $.28$ Terminal dribble 0.91 $0.82-1.02$ $.10$ Storage symptoms $=$ $=$ $=$ Perceived frequency 2.93 $2.35-3.66$ $<.001$ Nocturia 1.22 $1.10-1.34$ $<.001$ Urgency with fear of leaking 1.22 $1.06-1.39$ $<.001$ Urgency incontinence 1.92 $1.43-2.57$ $<.001$ Urgency incontinence: laughing 1.03 $0.68-1.54$ $.90$ Stress incontinence: sneezing 1.26 $0.92-1.72$ $.15$ Stress incontinence: sneezing 1.20 $0.81-1.78$ $.36$ heavy objects $.57$ $.589$ $.57-3.64$ $.59$ Stress incontinence: no reason 0.96	Hyperlipidemia	1.04	0.82-1.30	.75
Voiding symptoms Weak stream 1.12 $0.99-1.27$ $.08$ Split stream 0.93 $0.83-1.05$ $.24$ Intermittency 1.02 $0.90-1.16$ $.73$ Hesitancy 1.26 $1.10-1.45$ $<.001$ Straining 1.07 $0.94-1.22$ $.28$ Terminal dribble 0.91 $0.82-1.02$ $.10$ Storage symptoms $Perceived frequency$ 2.93 $2.35-3.66$ $<.001$ Nocturia 1.22 $1.10-1.34$ $<.001$ Urgency 0.94 $0.83-1.06$ $.31$ Urgency with fear of leaking 1.22 $1.06-1.39$ $<.001$ Urgency incontinence 1.92 $1.43-2.57$ $<.001$ Urgency incontinence: laughing 1.03 $0.68-1.54$ $.90$ Stress incontinence: sneezing 1.26 $0.92-1.72$ $.15$ Stress incontinence: coughing 0.93 $0.67-1.27$ $.64$ Stress incontinence: norturnal 2.35 $1.50-3.74$ $<.001$ enuresis (while sleep) Stress incontinence: no reason <td>Neurological disorder</td> <td>0.89</td> <td>0.55-1.41</td> <td>.61</td>	Neurological disorder	0.89	0.55-1.41	.61
Weak stream 1.12 $0.99-1.27$ $.08$ Split stream 0.93 $0.83-1.05$ $.24$ Intermittency 1.02 $0.90-1.16$ $.73$ Hesitancy 1.26 $1.10-1.45$ $<.001$ Straining 1.07 $0.94-1.22$ $.28$ Terminal dribble 0.91 $0.82-1.02$ $.10$ Strage symptomsPerceived frequency 2.93 $2.35-3.66$ $<.001$ Nocturia 1.22 $1.10-1.34$ $<.001$ Urgency 0.94 $0.83-1.06$ $.31$ Urgency with fear of leaking 1.22 $1.06-1.39$ $<.001$ Urgency incontinence— 1.92 $1.43-2.57$ $<.001$ frequency [†] $Stress$ incontinence: laughing 1.03 $0.68-1.54$ $.90$ Stress incontinence: laughing 1.03 $0.68-1.54$ $.90$ Stress incontinence: coughing 0.93 $0.67-1.27$ $.64$ Stress incontinence: coughing 0.93 $0.67-1.27$ $.64$ Stress incontinence: noturnal 2.35 $1.50-3.74$ $<.001$ enuresis (while sleep) $Stress incontinence: no reason0.960.57-1.65.89Stress incontinence: no reason0.960.57-1.$	Urinary symptoms (yes)			
Split stream 0.93 0.83-1.05 .24 Intermittency 1.02 0.90-1.16 .73 Hesitancy 1.26 1.10-1.45 <.001	Voiding symptoms			
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Weak stream	1.12	0.99-1.27	.08
Hesitancy1.26 $1.0-1.45$ <.001Straining1.07 $0.94-1.22$.28Terminal dribble 0.91 $0.82-1.02$.10Storage symptomsPerceived frequency 2.93 $2.35-3.66$ <.001	Split stream	0.93	0.83-1.05	.24
Straining 1.07 $0.94-1.22$.28 Terminal dribble 0.91 $0.82-1.02$.10 Storage symptoms	Intermittency	1.02	0.90-1.16	.73
Terminal dribble 0.91 $0.82-1.02$ $.10$ Storage symptoms Perceived frequency 2.93 $2.35-3.66$ $<.001$ Nocturia 1.22 $1.10-1.34$ $<.001$ Urgency 0.94 $0.83-1.06$ $.31$ Urgency with fear of leaking 1.22 $1.06-1.39$ $<.001$ Urgency incontinence— 1.92 $1.43-2.57$ $<.001$ Urgency incontinence 1.92 $1.43-2.57$ $<.001$ frequency [†] Stress incontinence: laughing 1.03 $0.68-1.54$ $.90$ Stress incontinence: sneezing 1.26 $0.92-1.72$ $.15$ Stress incontinence: coughing 0.93 $0.67-1.27$ $.64$ Stress incontinence: coughing 1.20 $0.81-1.78$ $.36$ heavy objects Stress incontinence: nocturnal 2.35 $1.50-3.74$ $<.001$ enuresis (while sleep) Stress incontinence: no reason 0.96 $0.57-1.65$ $.89$ $.59$ sexual activity Postmicturition symptoms Incontinence or dribble 1.31 $0.94-1.83$ $.11$ <td>Hesitancy</td> <td>1.26</td> <td>1.10-1.45</td> <td><.001</td>	Hesitancy	1.26	1.10-1.45	<.001
Storage symptoms Perceived frequency 2.93 $2.35-3.66$ $<.001$ Nocturia 1.22 $1.10-1.34$ $<.001$ Urgency 0.94 $0.83-1.06$ $.31$ Urgency with fear of leaking 1.22 $1.06-1.39$ $<.001$ Urgency with fear of leaking 1.22 $1.06-1.39$ $<.001$ Urgency incontinence— 1.92 $1.43-2.57$ $<.001$ Urgency incontinence: 1.92 $1.43-2.57$ $<.001$ frequency [†] Stress incontinence: laughing 1.03 $0.68-1.54$ $.90$ Stress incontinence: sneezing 1.26 $0.92-1.72$ $.15$ Stress incontinence: coughing 0.93 $0.67-1.27$ $.64$ Stress incontinence: exercising 1.71 $1.21-2.42$ $<.001$ Stress incontinence: nocturnal 2.35 $1.50-3.74$ $<.001$ enuresis (while sleep) Stress incontinence: no reason 0.96 $0.57-1.65$ $.89$ Stress incontinence: during 1.16 $0.68-2.03$ $.59$ sexual activity 1.31 <td< td=""><td>Straining</td><td>1.07</td><td>0.94-1.22</td><td>.28</td></td<>	Straining	1.07	0.94-1.22	.28
$\begin{array}{c ccccc} \mbox{Perceived frequency} & 2.93 & 2.35-3.66 & <.001 \\ \mbox{Nocturia} & 1.22 & 1.10-1.34 & <.001 \\ \mbox{Urgency} & 0.94 & 0.83-1.06 & .31 \\ \mbox{Urgency with fear of leaking} & 1.22 & 1.06-1.39 & <.001 \\ \mbox{Urgency incontinence} & 1.92 & 1.43-2.57 & <.001 \\ \mbox{frequency}^{\dagger} & & & & & & & & & & & & & & & & & & &$	Terminal dribble	0.91	0.82-1.02	.10
Nocturia 1.22 $1.0-1.34$ $<.001$ Urgency 0.94 $0.83-1.06$ $.31$ Urgency with fear of leaking 1.22 $1.06-1.39$ $<.001$ Urgency with fear of leaking 1.22 $1.06-1.39$ $<.001$ Urgency incontinence— 1.92 $1.43-2.57$ $<.001$ Urgency incontinence: laughing 1.03 $0.68-1.54$ $.90$ Stress incontinence: sneezing 1.26 $0.92-1.72$ $.15$ Stress incontinence: coughing 0.93 $0.67-1.27$ $.64$ Stress incontinence: exercising 1.71 $1.21-2.42$ $<.001$ Stress incontinence: lifting 1.20 $0.81-1.78$ $.36$ heavy objects Stress incontinence: nocturnal 2.35 $1.50-3.74$ $<.001$ enuresis (while sleep) Stress incontinence: no reason 0.96 $0.57-1.65$ $.89$ Stress incontinence: during 1.16 $0.68-2.03$ $.59$ sexual activity $.90$ $.59$ $.59$ postmic	Storage symptoms			
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$	Perceived frequency	2.93	2.35-3.66	<.001
Urgency with fear of leaking 1.22 $1.06-1.39$ $<.001$ Urgency incontinence— 1.92 $1.43-2.57$ $<.001$ frequency [†] 1.03 $0.68-1.54$ $.90$ Stress incontinence: laughing 1.03 $0.68-1.54$ $.90$ Stress incontinence: sneezing 1.26 $0.92-1.72$ $.15$ Stress incontinence: coughing 0.93 $0.67-1.27$ $.64$ Stress incontinence: exercising 1.71 $1.21-2.42$ $<.001$ Stress incontinence: lifting 1.20 $0.81-1.78$ $.36$ heavy objects S S S S Stress incontinence: nocturnal 2.35 $1.50-3.74$ $<.001$ enuresis (while sleep) S S S Stress incontinence: no reason 0.96 $0.57-1.65$ $.89$ Stress incontinence: during 1.16 $0.68-2.03$ $.59$ sexual activity P S S S Postmicturition symptoms I I $0.94-1.83$ $.11$	Nocturia	1.22	1.10-1.34	<.001
Urgency incontinence— 1.92 $1.43-2.57$ $<.001$ frequency [†] Stress incontinence: laughing 1.03 $0.68-1.54$ $.90$ Stress incontinence: sneezing 1.26 $0.92-1.72$ $.15$ Stress incontinence: coughing 0.93 $0.67-1.27$ $.64$ Stress incontinence: exercising 1.71 $1.21-2.42$ $<.001$ Stress incontinence: lifting 1.20 $0.81-1.78$ $.36$ heavy objects Stress incontinence: nocturnal 2.35 $1.50-3.74$ $<.001$ enuresis (while sleep) Stress incontinence: no reason 0.96 $0.57-1.65$ $.89$ Stress incontinence: during 1.16 $0.68-2.03$ $.59$ sexual activity $Postmicturition symptoms$ $Incontinence or dribble$ 1.31 $0.94-1.83$ $.11$	Urgency	0.94	0.83-1.06	.31
$\begin{array}{c ccccc} & & & & & & & & & & & & & & & & &$	Urgency with fear of leaking	1.22	1.06-1.39	<.001
Stress incontinence: laughing 1.03 0.68–1.54 .90 Stress incontinence: sneezing 1.26 0.92–1.72 .15 Stress incontinence: coughing 0.93 0.67–1.27 .64 Stress incontinence: exercising 1.71 1.21–2.42 <.001	Urgency incontinence-	1.92	1.43-2.57	<.001
Stress incontinence: sneezing 1.26 0.92–1.72 .15 Stress incontinence: coughing 0.93 0.67–1.27 .64 Stress incontinence: exercising 1.71 1.21–2.42 <.001	frequency [†]			
Stress incontinence: coughing0.930.67–1.27.64Stress incontinence: exercising1.711.21–2.42<.001	Stress incontinence: laughing	1.03	0.68-1.54	.90
Stress incontinence: exercising1.711.21–2.42<.001Stress incontinence: lifting1.200.81–1.78.36heavy objects	Stress incontinence: sneezing	1.26	0.92-1.72	.15
Stress incontinence: lifting1.200.81–1.78.36heavy objects.351.50–3.74<.001	Stress incontinence: coughing	0.93	0.67-1.27	.64
heavy objects Stress incontinence: nocturnal 2.35 1.50–3.74 <.001 enuresis (while sleep) Stress incontinence: no reason 0.96 0.57–1.65 .89 Stress incontinence: during 1.16 0.68–2.03 .59 sexual activity Postmicturition symptoms Incontinence or dribble 1.31 0.94–1.83 .11	Stress incontinence: exercising	1.71	1.21-2.42	<.001
Stress incontinence: nocturnal2.351.50–3.74<.001enuresis (while sleep)Stress incontinence: no reason0.960.57–1.65.89Stress incontinence: during1.160.68–2.03.59sexual activityPostmicturition symptomsIncontinence or dribble1.310.94–1.83.11	Stress incontinence: lifting	1.20	0.81-1.78	.36
enuresis (while sleep) Stress incontinence: no reason 0.96 0.57–1.65 .89 Stress incontinence: during 1.16 0.68–2.03 .59 sexual activity <i>Postmicturition symptoms</i> Incontinence or dribble 1.31 0.94–1.83 .11	heavy objects			
Stress incontinence: no reason0.960.57–1.65.89Stress incontinence: during1.160.68–2.03.59sexual activityPostmicturition symptomsIncontinence or dribble1.310.94–1.83.11		2.35	1.50-3.74	<.001
Stress incontinence: no reason0.960.57–1.65.89Stress incontinence: during1.160.68–2.03.59sexual activityPostmicturition symptomsIncontinence or dribble1.310.94–1.83.11	enuresis (while sleep)			
Stress incontinence: during1.160.68–2.03.59sexual activityPostmicturition symptomsIncontinence or dribble1.310.94–1.83.11	(1)	0.96	0.57-1.65	.89
sexual activity <i>Postmicturition symptoms</i> Incontinence or dribble 1.31 0.94–1.83 .11	Stress incontinence: during	1.16		.59
Postmicturition symptomsIncontinence or dribble1.310.94–1.83.11	0			
Incontinence or dribble 1.31 0.94–1.83 .11				
		1.31	0.94-1.83	.11
	Incomplete emptying	1.05		.35

* P-value <.05 was considered to be statistically significant.

⁺ Categorical urgency incontinence (<1 month, a few times a month, a few times a week, daily, many times daily).

Fewer than half of individuals with LUTS in our study consulted a healthcare professional for urinary symptoms. Embarrassment relating to cultural/social convention has previously been suggested as a reason for reluctance among Chinese women to seek healthcare for urinary incontinence. Additional barriers may include treatment costs, low QOL expectations, and lack of education. Without seeking healthcare, treatment is unlikely to be optimal. Therefore, our data indicate that treatment could be improved and that the impact of LUTS on QOL could be reduced. Education of both the public and physicians could help increase diagnosis and treatment rates. In addition, efforts to reduce stigma could be valuable.^[40]

Overall, the results for China from our study are consistent with the results for the whole study including South Korea and Taiwan. The clearest difference between China and the overall population is that higher percentages of individuals in China visited healthcare professionals because of urinary tract symptoms. Also, the prevalence of OAB was higher in China than in the other 2 countries.

Strengths of our study include the large sample size, balanced numbers of men and women, and the use of well-established and validated assessments.^[41,42] There are also some limitations to consider. The internet-based approach introduces potential for bias because the internet penetration rate was ~50% in China at the time of the study^[43]; internet availability may be limited in lower social classes where the unmet needs for LUTS management may be most important. As with all telephone or internetbased surveys, symptom prevalence could potentially be falsely raised by the inclusion of individuals who had a urinary catheter either following urinary tract surgery, which can be associated with temporary LUTS, or for reasons other than urinary tract diseases. Conversely, a lower prevalence of LUTS may be observed if individuals received treatment to control their symptoms. In addition, there is a lack of information to show the extent of coverage across different regions of China and ethnicities. Finally, oestrogen deficiency occurring postmenopause is associated with LUTS in women,^[44] but related demographic characteristics such as hysterectomy and menopause status were not collected in our study.

5. Conclusion

LUTS affect the majority of adults aged \geq 40 years in China, and prevalence increases with increasing age. LUTS are associated with impairment of QOL and mental health, but fewer than half of individuals in China with LUTS seek healthcare for their symptoms. There is therefore a need to improve awareness of the condition, which should improve rates of diagnosis and effective treatment.

Acknowledgments

The authors would like to thank the participants of the study for their time, and Nanjangud Shankar Narasimhamurthy and Koni Raviprakash for statistical analyses. Editorial support, including writing assistance, was provided by Ken Sutor BSc and Jackie van Bueren BSc of Envision Scientific Solutions, funded by Astellas Pharma Global Development.

Author contributions

- Conceptualization: Jian-Ye Wang, Limin Liao, Ming Liu, Budiwan Sumarsono, Min Cong.
- Data curation: Budiwan Sumarsono.
- Formal analysis: Budiwan Sumarsono.
- Methodology: Jian-Ye Wang, Limin Liao, Ming Liu, Budiwan Sumarsono, Min Cong.
- Validation: Budiwan Sumarsono.
- Writing review & editing: Jian-Ye Wang, Limin Liao, Ming Liu, Budiwan Sumarsono, Min Cong.

References

 Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Subcommittee of the International Continence Society. Neurourol Urodyn 2002;21:167–78.

- [2] Coyne KS, Sexton CC, Thompson CL, et al. The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int 2009;104:352–60.
- [3] Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 2006;50:1306–14.
- [4] Wang Y, Hu H, Xu K, et al. Prevalence, risk factors and the bother of lower urinary tract symptoms in China: a population-based survey. Int Urogynecol J 2015;26:911–9.
- [5] Choi EP, Lam CL, Chin WY. The health-related quality of life of Chinese patients with lower urinary tract symptoms in primary care. Qual Life Res 2014;23:2723–33.
- [6] Coyne KS, Sexton CC, Kopp ZS, et al. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS. BJU Int 2011;108:1459–71.
- [7] Wang Y, Xu K, Hu H, et al. Prevalence, risk factors, and impact on health related quality of life of overactive bladder in China. Neurourol Urodyn 2011;30:1448–55.
- [8] Zhang X, Zhang J, Chen J, et al. Prevalence and risk factors of nocturia and nocturia-related quality of life in the Chinese population. Urol Int 2011;86:173–8.
- [9] Azam U, Castleden M, Turner D. Economics of lower urinary tract symptoms (LUTS) in older people. Drugs Aging 2001;18:213–23.
- [10] Coyne KS, Wein AJ, Tubaro A, et al. The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int 2009;(103 suppl 3):4–11.
- [11] Coyne KS, Sexton CC, Irwin DE, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int 2008;101:1388–95.
- [12] Zhang K, He LJ, Yu W, et al. Association of depression/anxiety with lower urinary tract symptoms and erectile dysfunction in Chinese men aged from 22 to 50 years. Beijing Da Xue Xue Bao 2013;45:609–12.
- [13] Choi H, Park JY, Yeo JK, et al. Population-based survey on disease insight, quality of life, and health-seeking behavior associated with female urinary incontinence. Int Neurourol J 2015;19:39–46.
- [14] Chapple C, Castro-Diaz D, Chuang Y-C, et al. Prevalence of LUTS in China, Taiwan and South Korea: results from a cross-sectional, population-based study. Adv Ther 2017;34:1953–65.
- [15] Chuang YC, Liu SP, Lee KS, et al. Prevalence of overactive bladder in China, Taiwan and South Korea: results from a cross-sectional, population-based study. LUTS 2017;doi: 10. 1111/luts.12193. Epub ahead of print.
- [16] Lee KS, Yoo TK, Liao L, et al. Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study. BMC Urol 2017;17:108.
- [17] Lee H, Jeong SJ. Epidemiology of lower urinary tract symptoms: emphasis on the status in Korea. Korean J Urol 2014;55:300–8.
- [18] Zhang L, Zhu L, Xu T, et al. A population-based survey of the prevalence, potential risk factors, and symptom-specific bother of lower urinary tract symptoms in adult Chinese women. Eur Urol 2015;68:97–112.
- [19] Zhang W, Song Y, He X, et al. Prevalence and risk factors of lower urinary tract symptoms in Fuzhou Chinese women. Eur Urol 2005;48:309–13.
- [20] Yee CH, Li JK, Lam HC, et al. The prevalence of lower urinary tract symptoms in a Chinese population, and the correlation with uroflowmetry and disease perception. Int Urol Nephrol 2014;46:703–10.
- [21] Blanker MH, Bosch JL, Groeneveld FP, et al. Erectile and ejaculatory dysfunction in a community-based sample of men 50 to 78 years old: prevalence, concern, and relation to sexual activity. Urology 2001;57:763–8.
- [22] Abrams P, Smith AP, Cotterill N. The impact of urinary incontinence on health-related quality of life (HRQoL) in a real-world population of women aged 45–60 years: results from a survey in France, Germany, the UK and the USA. BJU Int 2015;115:143–52.

- [23] Avery JC, Stocks NP, Duggan P, et al. Identifying the quality of life effects of urinary incontinence with depression in an Australian population. BMC Urol 2013;13:11.
- [24] Hunter DJ, McKee M, Black NA, et al. Health status and quality of life of British men with lower urinary tract symptoms: results from the SF-36. Urology 1995;45:962–71.
- [25] Coyne KS, Kvasz M, Ireland AM, et al. Urinary incontinence and its relationship to mental health and health-related quality of life in men and women in Sweden, the United Kingdom, and the United States. Eur Urol 2012;61:88–95.
- [26] Choi EP, Lam CL, Chin WY. Mental health of Chinese primary care patients with lower urinary tract symptoms. Psychol Health Med 2016;21:113–27.
- [27] Chung RY, Leung JC, Chan DC, et al. Lower urinary tract symptoms (LUTS) as a risk factor for depressive symptoms in elderly men: results from a large prospective study in Southern Chinese men. PLoS One 2013;8:e76017.
- [28] Song J, Shao Q, Tian Y, et al. Lower urinary tract symptoms, erectile dysfunction, and their correlation in men aged 50 years and above: a cross-sectional survey in Beijing, China. Med Sci Monit 2014;20: 2806–10.
- [29] Irwin DE, Milsom I, Kopp Z, et al. Prevalence, severity, and symptom bother of lower urinary tract symptoms among men in the EPIC study: impact of overactive bladder. Eur Urol 2009;56:14–20.
- [30] Drake MJ. Do we need a new definition of the overactive bladder syndrome? ICI-RS 2013. Neurourol Urodyn 2014;33:622–4.
- [31] Zhang XH, Li X, Zhang Z, et al. Prevalence of overactive bladder in a community-based male aging population. Zhonghua Wai Ke Za Zhi 2010;48:1763–6.
- [32] Wen JG, Li JS, Wang ZM, et al. The prevalence and risk factors of OAB in middle-aged and old people in China. Neurourol Urodyn 2014; 33:387–91.
- [33] Na YQ, Ye ZQ, Sun YH, Sun G. Chinese Guidelines on Urologic Diseases. 2nd edn. People's Medical Publishing House, Beijing, China: 2014.
- [34] Andersson KE. Mechanisms of disease: central nervous system involvement in overactive bladder syndrome. Nat Clin Pract Urol 2004;1:103–8.
- [35] Arrellano-Valdez F, Urrutia-Osorio M, Arroyo C, et al. A comprehensive review of urologic complications in patients with diabetes. Springerplus 2014;3:549.
- [36] Madhu C, Enki D, Drake MJ, et al. The functional effects of cigarette smoking in women on the lower urinary tract. Urol Int 2015;95:478–82.
- [37] Kim SY, Bang W, Choi HG. Analysis of the prevalence of and factors associated with overactive bladder in adult Korean women. PLoS One 2017;12:e0185592.
- [38] Maserejian NN, Kupelian V, Miyasato G, et al. Are physical activity, smoking and alcohol consumption associated with lower urinary tract symptoms in men or women? Results from a population based observational study. J Urol 2012;188:490–5.
- [39] Jo JK, Lee S, Kim YT, et al. Analysis of the risk factors for overactive bladder on the basis of a survey in the community. Korean J Urol 2012;53:541–6.
- [40] Wang C, Li J, Wan X, et al. Effects of stigma on Chinese women's attitudes towards seeking treatment for urinary incontinence. J Clin Nurs 2015;24:1112–21.
- [41] Hung MJ, Chou CL, Yen TW, et al. Development and validation of the Chinese Overactive Bladder Symptom Score for assessing overactive bladder syndrome in a RESORT study. J Formos Med Assoc 2013; 112:276–82.
- [42] Choi EP, Lam CL, Chin WY. Validation of the International Prostate Symptom Score in Chinese males and females with lower urinary tract symptoms. Health Qual Life Outcomes 2014;12:1.
- [43] Internet World Stats. Internet usage in Asia. 2016. Available at: https:// www.internetworldstats.com/stats3.htm. Accessed July 10, 2018.
- [44] Iosif CS, Bekassy Z. Prevalence of genito-urinary symptoms in the late menopause. Acta Obstet Gynecol Scand 1984;63:257–60.